Rheumatology

Back to articles

NSAIDs: Remaining GI-Protective Options Limited

KEY POINT

Following last month’s removal of valdecoxib (Bextra—Pfizer) from the U.S. market, few choices remain for GI-sensitive patients requiring long-term treatment with NSAIDs for conditions such as osteoarthritis: the COX-2–selective agent celecoxib (Celebrex—Pfizer), diclofenac/misoprostol (Arthrotec—Pfizer), and lansoprazole/ naproxen (Prevacid NapraPac—Tap Pharmaceuticals).

SOURCES

Pilotto A et al. The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: the role of gastroprotective drugs. Aging Clin Exp Res. 2003;15:494–9.